



Company Name: Linical Co., Ltd.
Representative: Kazuhiro Hatano
President & CEO
(TSE code: 2183)

05 June 2019

Linical Co., Ltd. announces the establishment of an affiliate company in Shanghai, People's Republic of China

Linical Co., Ltd. (hereinafter referred to as "Linical") hereby announces that it has completed procedures for the establishment (as published in the news release on 28 February 2019) of a wholly owned subsidiary in Shanghai, China on 28 May 2019, as described below;

1. Purpose of the establishment

The Linical group is advancing its global strategy by expanding its network and business overseas in the United States, Europe, and Asia in order to deliver a one-stop comprehensive service to our clients around the world.

Linical has an affiliate company in Beijing, China since the acquisition of Accelovance, Inc. last year. Linical Accelovance China Ltd. (Beijing, hereinafter "LAC") has been conducting business in China. LAC has been entrusted with several clinical trials from Japanese and European pharmaceutical companies.

In order to respond to the increasing need for clinical trials in China and to enhance client satisfaction in speed, quality and convenience, Linical China Co., Ltd. has been established in Shanghai, China.

Demand for clinical trials in China is expected to continue to increase. The establishment of Shanghai office, together with the existing Beijing office, expands the

coverage to a wider range of business territory in China. The optimal organization structure in China will be examined in the medium to long term.

2. Overview of the Subsidiary

1) Company name	Linical China Co., Ltd.
2) Location	Room 31, 26F Lippo Plaza, 222 Middle Huaihai Road, Huangpu District, Shanghai, people's republic of China
3) Representative officer	(Mr.) Jun Kawai (Executive Vice President and Head of Quality Control of Linical Co., Ltd.)
4) Main business lines	CRO business
5) Capital	RMB 1,000,000 (approx. JPY 15 million *1)
6) Establishment date	28 May 2019
7) Fiscal year end	31 December
8) Ownership ratio	100% owned by Linical Co., Ltd.

*1: Calculated on the basis of 1RMB=15.62JPY (Inter-bank rate as of 5 June 2019)

*2: Fiscal year is fixed under Chinese law.

3. Schedule

- Date of resolution : 28 February 2019
- Date of Establishment : 28 May 2019

4. Future outlook

The establishment of the subsidiary will have no significant effect on the consolidated operating results of Linical Co., Ltd. for the fiscal year ending 31 March 2020.

END

Notes: This is a summary translation of the press release original drafted in Japanese for the disclosure required in compliance with the TSE regulations.